The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-29 and is reviewed periodically as new material appears.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
This low gamma ray production rate makes it difficult to use for identification of the isotope; rather than gamma ray spectroscopy, alpha spectroscopy is the best method of measuring it. Owing to its much shorter half-life, a milligram of 210Po emits as many alpha particles per second as 5 grams of 226Ra (that is, a milligram is 5 curies). A few curies of 210Po emit a blue glow caused by excitation of surrounding air. 210Po occurs in minute amounts in nature, where it is the penultimate isotope in the uranium series decay chain. It is generated via beta decay from 210Pb and 210Bi. The astrophysical s-process is terminated by the decay of 210Po, as the neutron flux is insufficient to lead to further neutron captures in the short lifetime of 210Po. Instead, 210Po alpha decays to 206Pb, which then captures more neutrons to become 210Po and repeats the cycle, thus consuming the remaining neutrons. This results in a buildup of lead and bismuth, and ensures that heavier elements such as thorium and uranium are only produced in the much faster r-process.
== Early life == Peters was born Braden Eric Peters to a businessman father and stay-at-home mother. He was raised in Hoboken, New Jersey, and attended Seton Hall Preparatory School in West Orange, New Jersey. He has stated that he became interested in looksmaxxing—a term originating on incel message boards in the early 2010s that describes the process of making oneself as physically attractive as possible—in high school, which he has attributed to wanting to influence others politically by becoming more attractive. Peters described his life during the COVID-19 lockdowns as being "online for 14 hours a day", browsing looksmaxxing forums, playing Grand Theft Auto V and skipping online classes. Peters has stated in interviews that he would often hide his testosterone supplements from his parents, and when caught, he would be sent to live with his grandmother. Peters claims to have been expelled after "just three weeks" from Sacred Heart University in Fairfield, Connecticut for his use of "peptides and 'roids".
=== Cancer === PARP1 is involved in base excision repair (BER), single- and double-strand break repair, and chromosomal stability. It is also involved in transcriptional regulation through its facilitation of protein–protein interactions. PARP1 uses NAD+ in order to perform its function in apoptosis. If a PARP becomes overactive the cell will have decreased levels of NAD+ cofactor as well as decreased levels of ATP and thus will undergo necrosis. This is important in carcinogenesis because it could lead to the selection of PARP1 deficient cells (but not depleted) due to their survival advantage during cancer growth. Susceptibility to carcinogenesis under PARP1 deficiency depends significantly on the type of DNA damage incurred. There are many implications that various PARPs are involved in preventing carcinogenesis. As stated previously, PARP1 and PARP2 are involved in BER and chromosomal stability. PARP3 is involved in centrosome regulation. Tankyrase is another (ADP-ribosyl)polymerase that is involved in telomere length regulation. PARP1 inhibition has also been widely studied in anticancer therapeutics. The mechanism of action of a PARP1 inhibitor is to enhance the damage done by chemotherapy on the cancerous DNA by disallowing the reparative function of PARP1 in BRCA1/2 deficient individuals . PARP14 is another ADP-ribosylating enzyme that has been well-studied in regards to cancer therapy targets; it is a signal transducer and activator of STAT6 transcription-interacting protein, and was shown to be associated with the aggressiveness of B-cell lymphomas.
=== Oral bacteria === Erythritol is tooth-friendly; since it cannot be metabolized by oral bacteria, it does not contribute to tooth decay. In addition, erythritol, like xylitol, has antibacterial effects against streptococci bacteria, reduces dental plaque, and may be protective against tooth decay.
Sources: en.wikipedia.org
=== Special populations === Pregnancy: studies in lab animals showed no harm to the baby. However, a comparable well-controlled study has not been performed in pregnant women. Nursing: breast milk has been shown to contain small amounts of labetalol (0.004% original dose). Prescribers should be cautious in the use of labetalol for nursing mothers. Pediatric: no studies have established safety or usefulness in this population. Geriatric: Due to an increased likelihood of experiencing orthostatic symptoms such as dizziness, product labelling recommends that elderly patients receive counselling regarding these side effects during labetalol treatment. Furthermore, because drug elimination is reduced in older demographics, lower maintenance doses are typically sufficient to achieve therapeutic effects.
DHX8 protein has its main focuses of expression in the brain, especially in the cerebellum where it can be found mostly in Purkinje cells. Other important are the prostate and the gallbladder, which are zones where the polypetide is found also highly expressed. DHX8 protein is not expressed in all tissues and organs significantly, some clear examples are the bone marrow or the soft tissue (Peripheral nerve), where we do not have enough quantity of the protein to be representative.
It’s a fight for our national security." He advocated for a special inspector general to monitor the aid given to Ukraine following Russia's invasion. Kennedy expressed concern that money was being misspent, saying, "Ukraine is not without flaws. We've heard several unsettling reports of bad actors exploiting our generosity… We trust that our friends in Ukraine take corruption seriously. We must verify, too."
Sources: en.wikipedia.org
== History == The tanning effect of dihydroxyacetone (DHA) was discovered in the 1950s by Eva Wittgenstein at Cincinnati Children's Hospital, who observed that DHA used in an oral treatment stained the skin brown on contact. The first commercial DHA self-tanner, Man-Tan, appeared in 1959, followed by Coppertone's "QT" (Quick Tan) in 1960; both produced an orange-toned result that gave early self-tanners a poor reputation. Reformulated products and, from the late 1990s, automated spray-tan booths broadened the market.
Most nitrogenases contain an iron–molybdenum cofactor FeMoco, which is believed to contain either Mo(III) or Mo(IV). By contrast Mo(VI) and Mo(IV) are complexed with molybdopterin in all other molybdenum-bearing enzymes. Molybdenum is an essential element for all higher eukaryote organisms, including humans. A species of sponge, Theonella conica, is known for hyperaccumulation of molybdenum.
Russia launched about 85 to 100 missiles at a number of Ukrainian cities. The strategic bombing campaign caused severe shortages of electricity and water at multiple cities. According to the Ukrainian Air Force some 77 of 96 Russian missiles were shot down. A Pentagon official claimed the Russian plan was to exhaust the Ukrainian air defences. At one stage some 50 missiles were in combat "within minutes" near the Polish border. A missile crossed over the Ukrainian-Polish border and struck the village of Przewodów, killing two civilians. Top leaders in Poland held an emergency meeting. Initial assessments by the United States found that the missile was likely to have been an air defence missile fired by Ukrainian forces at an incoming Russian missile. According to Ukraine's Operational Command South, Ukrainian rocket and artillery units attacked Russian positions on the left bank of the Dnipro River and in the area of the Kinburn Spit.
=== Allergy === Molecular diagnostics is increasingly used in allergology, especially for food and respiratory allergy. Conventional diagnosis is based on clinical history, skin-prick testing and measurement of serum allergen-specific IgE to whole allergen extracts. Molecular-based allergy diagnostics, also called component-resolved diagnostics, measures IgE to individual allergen molecules rather than only to extracts. This can help distinguish genuine sensitization from cross-reactivity, refine assessment of clinical risk in some allergies, and support decisions about allergen immunotherapy. Multiplex platforms, such as Allergy Explorer (ALEX), can test IgE reactivity to many allergen extracts and molecular components in a single assay. Precision allergy molecular diagnosis (PAMD®) is a broader diagnostic approach using molecular IgE profiles to guide prognosis, risk assessment and personalized management, although results must be interpreted together with the patient’s clinical history.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.